EIM
EPZM

Essex Investment Management’s Epizyme, Inc EPZM Stock Holding History

Essex Investment Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-47,343
Closed -$812K – 368
2017
Q1 		$812K Sell
47,343
-12,433
-21% -$166K 0.13% 214
2016
Q4 		$723K Buy
+59,776
New +$624K 0.12% 202

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Essex Investment Management's EPZM Position: Q2 2017 in Review

Essex Investment Management sold out of Epizyme, Inc (EPZM) in Q2 2017, closing a stake of 47,343 shares — an estimated $812K sold.

Essex Investment Management first reported a position in EPZM in Q4 2016 and held it in 2 quarters. The position peaked at $812K in Q1 2017. 108 funds tracked by Wall St. Rank hold EPZM as of Q2 2017.

  • Essex Investment Management reported no remaining Epizyme, Inc position as of Q2 2017 after selling out during the quarter.
  • Essex Investment Management sold 47,343 Epizyme, Inc shares in Q2 2017, an estimated $812K.
  • Essex Investment Management first reported a position in Epizyme, Inc in Q4 2016 and held it in 2 quarters.
  • Essex Investment Management's Epizyme, Inc position peaked at $812K in Q1 2017.
  • 108 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2017.

Based on Essex Investment Management's 13F filing for Q2 2017, filed 28 Jul 2017.